These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18240910)

  • 1. Use of genetic and nongenetic factors in warfarin dosing algorithms.
    Wu AH
    Pharmacogenomics; 2007 Jul; 8(7):851-61. PubMed ID: 18240910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of pharmacogenetics in anticoagulation therapy.
    Hill CE; Duncan A
    Clin Lab Med; 2008 Dec; 28(4):513-24. PubMed ID: 19059059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.
    Gulseth MP; Grice GR; Dager WE
    Am J Health Syst Pharm; 2009 Jan; 66(2):123-33. PubMed ID: 19139476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genetic and bioenvironmental factors associated with warfarin response in Colombian patients].
    Isaza C; Beltrán L; Henao J; Porras G; Pinzón A; Vallejos A; Machado J
    Biomedica; 2010; 30(3):410-20. PubMed ID: 21713343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
    McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC
    Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics and warfarin therapy.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Oct; (104):1-8. PubMed ID: 17912794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin sensitivity and genetic polymorphisms: should pharmacokinetic screening be part of anticoagulant dosing decisions?
    Baglin TP
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):656-7. PubMed ID: 16258463
    [No Abstract]   [Full Text] [Related]  

  • 9. Hematology consult: high-sensitivity warfarin genotype.
    Schwer C; Lamana S; Dasanu CA
    Conn Med; 2013; 77(10):581-5. PubMed ID: 24367840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
    Ruud E; Holmstrøm H; Bergan S; Wesenberg F
    Pediatr Blood Cancer; 2008 Mar; 50(3):710-3. PubMed ID: 17226852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is personalized medicine a dream or a reality?
    Morse BL; Kim RB
    Crit Rev Clin Lab Sci; 2015 Feb; 52(1):1-11. PubMed ID: 25181036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-drug interactions between warfarin and psychotropics: updated review of the literature.
    Nadkarni A; Oldham MA; Howard M; Berenbaum I
    Pharmacotherapy; 2012 Oct; 32(10):932-42. PubMed ID: 23033232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral anticoagulation: a critique of recent advances and controversies.
    Pirmohamed M; Kamali F; Daly AK; Wadelius M
    Trends Pharmacol Sci; 2015 Mar; 36(3):153-63. PubMed ID: 25698605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualizing warfarin therapy.
    Reynolds KK; Valdes R; Hartung BR; Linder MW
    Per Med; 2007 Feb; 4(1):11-31. PubMed ID: 29793302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin.
    Verhoef TI; Schalekamp T; Redekop WK; de Boer A; Maitland-van der Zee AH
    Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):375-8. PubMed ID: 20715914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches.
    Pavani A; Naushad SM; Uma A; Kutala VK
    Pharmacogenomics; 2014 Jun; 15(8):1125-32. PubMed ID: 25084205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible Strategies to Make Warfarin Dosing Algorithm Prediction More Accurately in Patients With Extreme Dose.
    Yan H; Yin JY; Zhang W; Li X
    Clin Pharmacol Ther; 2018 Feb; 103(2):184. PubMed ID: 28850705
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.
    Shetty HG; Fennerty AG; Routledge PA
    Clin Pharmacokinet; 1989 Apr; 16(4):238-53. PubMed ID: 2656051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing warfarin dosing using deep reinforcement learning.
    Anzabi Zadeh S; Street WN; Thomas BW
    J Biomed Inform; 2023 Jan; 137():104267. PubMed ID: 36494060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychotropic interactions with warfarin.
    Sayal KS; Duncan-McConnell DA; McConnell HW; Taylor DM
    Acta Psychiatr Scand; 2000 Oct; 102(4):250-5. PubMed ID: 11089724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.